关于暂不召开股东会的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-056 根据《上市公司重大资产重组管理办法》《上市公司证券发行注 册管理办法》《上市公司监管指引第 9 号——上市公司筹划和实施重 大资产重组的监管要求》《公开发行证券的公司信息披露内容与格式 关于暂不召开股东会的公告 准则第 26 号——上市公司重大资产重组》《深圳证券交易所上市公 司重大资产重组审核规则》等相关法律法规和规范性文件的要求，本 次交易尚需深圳证券交易所审核通过及中国证券监督管理委员会同 意注册后方可实施。 广州迈普再生医学科技股份有限公司 关于暂不召开股东会审议本次交易相关事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）拟筹 划发行股份及支付现金的方式收购广州易介医疗科技有限公司 100% 股权并募集配套资金暨关联交易事项（以下简称"本次交易"）。 公司于 2025 年 6 月 5 日召开了第三届董事会第十次会议及第三 届监事会第九次会议，审议通过了《关于公司发行股份及支付现金购 买资产并募 ...

证券代码：301033 证券简称：迈普医学 上市地点：深圳证券交易所 广州迈普再生医学科技股份有限公司 发行股份及支付现金购买资产并募集配套资金 暨关联交易预案（修订稿） | 项目 | 交易对方 | | --- | --- | | 购买资产交易对方 | 广州泽新医疗科技有限公司等 10 名交易对方 | | 募集配套资金认购方 | 广州易见医疗投资有限公司 | 二〇二五年八月 广州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易预案（修订稿） 本次交易完成后，本公司经营与收益变化由本公司自行负责；因本次交易引致的 投资风险，由投资者自行负责。 投资者在评价本次交易事项时，除本预案及其摘要内容以及同时披露的相关文件 外，还应认真考虑本预案及其摘要披露的各项风险因素。投资者若对本预案存在任何 疑问，应咨询自己的股票经纪人、律师、会计师或其他专业顾问。 2 上市公司声明 本公司、控股股东、全体董事、监事、高级管理人员保证本预案内容及其摘要内 容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。如因提供的信息、 出具的说明及确认存在虚假记载、误导性陈述或重大遗漏，给投资者造成损失的 ...

一、董事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）第三 届董事会第十二次会议于 2025 年 8 月 11 日上午 10:30 以现场和通讯 相结合的方式在公司会议室召开。本次会议通知已于 2025 年 8 月 8 日以邮件的方式发出。会议应出席董事 9 人，实际出席董事 9 人，其 中，袁玉宇先生、王建华先生以通讯方式出席会议。本次会议由董事 长袁玉宇先生召集并主持，公司全体董事出席了会议，全体高级管理 人员列席了会议。本次会议的召集、召开和表决程序符合国家有关法 律、行政法规及《广州迈普再生医学科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，会议形成的决议合法有效。 二、董事会会议审议情况 证券代码：301033 证券简称：迈普医学 公告编号：2025-053 广州迈普再生医学科技股份有限公司 第三届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 董事会决议公告 （2）定价基准日和发行价格 本次会议以记名方式投票表决，审议并通过了以下事项： （一）逐项审议通过《关于调整公司发行股份及支付现金 ...

调整并修订预案的公告 广州迈普再生医学科技股份有限公司关于 发行股份及支付现金购买资产并募集配套资金暨关联交易 调整募集配套资金认购对象、募集配套资金定价基准日及发 行价格并修订预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司""迈普 医学"）拟发行股份及支付现金的方式收购广州易介医疗科技有限公 司（以下简称"标的公司"）100%股权并募集配套资金暨关联交易事 项（以下简称"本次交易"），并已于 2025 年 6 月 6 日披露了《广 州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并 募集配套资金暨关联交易预案》等公告。 2025 年 8 月 11 日，公司召开第三届董事会第十二次会议，审议 通过《关于调整公司发行股份及支付现金购买资产并募集配套资金暨 关联交易之募集配套资金方案的议案》等议案。 一、调整募集配套资金认购对象并调整募集配套资金定价基准日 及发行价格的情况 （一）原募集配套资金认购对象、募集配套资金定价基准日及发 证券代码：301033 证券简称：迈普医学 公告编号：2025- ...

证券代码：301033 证券简称：迈普医学 公告编号：2025-054 广州迈普再生医学科技股份有限公司 关于本次交易方案募集配套资金认购对象、募集配套资金 提示性公告 定价基准日及发行价格之调整的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司""迈普 医学"）拟发行股份及支付现金的方式收购广州易介医疗科技有限公 司（以下简称"标的公司"）100%股权并募集配套资金暨关联交易事 项（以下简称"本次交易"），并已于 2025 年 6 月 6 日披露了《广 州迈普再生医学科技股份有限公司发行股份及支付现金购买资产并 募集配套资金暨关联交易预案》等公告。 2025 年 8 月 11 日，公司召开第三届董事会第十二次会议，审议 通过《关于调整公司发行股份及支付现金购买资产并募集配套资金暨 关联交易之募集配套资金方案的议案》等议案。 关于本次交易方案募集配套资金认购对象、募集配套资金定价基 准日及发行价格之调整不构成原重组交易方案的重大调整，其中，关 于募集配套资金方案作出如下调整： 提示性公告 一、调整募集 ...

Company Performance - MaiPu Medical's stock price reached a historical high, increasing by 4.15% to 83.79 yuan, with a trading volume of 407,000 shares and a transaction amount of 33.12 million yuan, resulting in a turnover rate of 0.73% [2] - The latest total market capitalization of the company in A-shares is 5.581 billion yuan, while the circulating market capitalization is 4.698 billion yuan [2] - The company's Q1 report shows a revenue of 73.70 million yuan, representing a year-on-year growth of 28.84%, and a net profit of 24.16 million yuan, with a year-on-year increase of 61.68% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which MaiPu Medical belongs, has an overall increase of 0.29%, with 242 stocks rising, including notable gainers like Sino Medical, Sanxin Medical, and Fuan Pharmaceutical, which rose by 13.82%, 13.50%, and 10.73% respectively [2] - Conversely, 238 stocks in the industry experienced declines, with major losers including Hitec Biology, Peking University Pharmaceutical, and Anglikang, which fell by 8.40%, 6.64%, and 5.41% respectively [2] Financing Data - As of August 11, the latest margin trading balance for MaiPu Medical is 55.33 million yuan, with a financing balance of 55.32 million yuan, reflecting a decrease of 7.13 million yuan over the past 10 days, which is a decline of 11.41% [2]

政策上，上周政策端进一步体现出对创新医疗药械的支持力度，工业和信息化部、国家发展改革委、教 育部、国家卫生健康委、 国务院国资委、中国科学院、国家药监局七部委发布《关于推动脑机接口产 业创新发展的实施意见》。国内将加强基 础软硬件攻关，打造高性能产品，将在 2027 年和 2030 年分 阶段展现出成果。其中，脑机接口赛道应用场景多元化、 产品及研发路径丰富，未来潜在空间巨大， 在国内政策加持下有望加速实现商业化普及。全球产品研发布局企业众多， 国内部分头部企业已经集 中在非侵入式领域产品取得多项技术突破，产品将迎来巨大商业化潜力 反内卷也在持续利好医疗器械行业的发展：7月3日，国家药监局关于发布优化全生命周期监管支持高端 医疗器械创新发展有关举措的公告，提出十大举措全力支持高端医疗器械重大创新。 近日，在政策反内卷号召、创新医疗器械支持下，国产医疗器械企业出海持续加速，今日盘中，全市场 规模最大的$医疗器械ETF(159883)$涨超2%，资金申购超1亿份，近一周份额增长14.8亿份，连续5天净 申购，资金持续疯狂涌入！ | 序号 | 代码 | 名称 | 涨跌幅 ▼ | | --- | --- | --- ...

Summary of the Conference Call for MaiPu Medical Company Overview - **Company**: MaiPu Medical - **Industry**: Medical Devices, specifically focusing on neurosurgical and neurointerventional products Key Points and Arguments 1. **Growth Phase**: MaiPu Medical has entered a high growth phase since 2023, benefiting from centralized procurement policies and new product launches, with an expected growth rate of 11% to 11.5% in 2024 [2][6] 2. **Product Certifications**: The hemostatic gauze has received EU CE and domestic NMPA certifications, expanding its application to general surgery, with expected revenue of approximately 36 million yuan in 2024 [2][7] 3. **Market Potential**: The domestic medical glue market is still in its cultivation stage, with a projected size of 500 million to 1.6 billion yuan, with only two competitors, MaiPu and Shandong Saisais, currently in the market [2][7] 4. **Impact of Centralized Procurement**: Centralized procurement policies are expected to promote the replacement of titanium with PEEK materials, benefiting hemostatic gauze through domestic substitution, and driving the growth of emerging products [2][8][9] 5. **Acquisition of YiJie Medical**: In June 2025, MaiPu Medical acquired 100% of YiJie Medical to expand into the neurointerventional field, enhancing market competitiveness [3][10] 6. **Neurointerventional Market Growth**: The domestic neurointerventional market is rapidly growing, with a significant increase in the number of stroke patients and improving surgical penetration rates [11][12] 7. **Domestic Production Rate**: The domestic neurointerventional device market has seen a compound growth rate of 16% from 2017 to 2022, with an increase in domestic production rates from 7% in 2020 to nearly 26% in 2024 [12] 8. **Concerns Over Acquisition**: There are concerns regarding the potential dilution of profit margins due to YiJie Medical's previous losses, but the overall revenue and profit growth trajectory is positive [15] 9. **Future Profitability Expectations**: Without considering the acquisition, the expected net profit for MaiPu Medical from 2025 to 2027 is projected to be 110 million, 160 million, and 220 million yuan, respectively, indicating strong growth potential [17] Additional Important Information - **R&D Investment**: MaiPu Medical has maintained a high R&D investment rate of over 15% from 2017 to 2022, focusing on building a product system centered around neurosurgical products [5] - **Market Competition**: The hemostatic gauze market is competitive, with major players like Johnson & Johnson, while the medical glue market is still developing with limited competition [7] - **Regulatory Environment**: The regulatory environment is stringent regarding related party transactions, reducing the likelihood of unreasonable pricing that could harm minority shareholders [15][16]

Core Viewpoint - The company is entering a high growth phase in its neurosurgery business, driven by new product launches and the impact of centralized procurement [3][4]. Group 1: Business Development - Before 2023, the company experienced a phase of low revenue, heavily reliant on a single product, with a focus on R&D and gradual product approvals [3]. - Post-2023, the impact of centralized procurement on the company's main product has diminished, stabilizing the business, while new products like hemostatic gauze and dural glue are expected to drive rapid revenue growth [3][4]. - The company is strategically expanding into the neurointervention sector, which has low penetration and domestic production rates, through the acquisition of Easy Medical [3][4]. Group 2: Acquisition Insights - Concerns regarding the acquisition include potential dilution of profit margins and pricing issues related to related-party transactions, but the regulatory environment minimizes these risks [4]. - The acquisition is expected to enhance channel synergy between neurosurgery and neurointervention, significantly expanding the company's growth potential [4]. - The current low shareholding ratio of the controlling shareholder may be improved through this acquisition, strengthening control over the company [4]. Group 3: Financial Projections - The company maintains its profit forecast, expecting net profits of 110 million, 160 million, and 220 million yuan for 2025-2027, representing year-on-year growth rates of 43.8%, 39.0%, and 40.5% respectively [5]. - The estimated earnings per share (EPS) for the same period are projected to be 1.70, 2.36, and 3.32 yuan [5]. - A target price of approximately 90 yuan is set based on a 38x PE valuation for 2026, maintaining a "recommended" rating [5].

Core Viewpoint - The company is entering a high growth phase in its neurosurgery business, driven by new product launches and centralized procurement initiatives, while also strategically expanding into the neurointervention market through the acquisition of Easy Medical [1][2]. Group 1: Neurosurgery Business Growth - Before 2023, the company had a small revenue base, heavily reliant on a single product, with a focus on R&D and gradual product approvals, but lacked commercial capabilities [1]. - Post-2023, the impact of centralized procurement on the hard dura mater product has stabilized, and new products like hemostatic gauze and dural glue are successfully ramping up sales, contributing to rapid revenue growth [1]. - The company expects profit growth in the next two years due to economies of scale and a slowdown in expense growth, indicating a transition to a high growth profit phase [1]. Group 2: Acquisition of Easy Medical - The acquisition of Easy Medical is aimed at enhancing the company's presence in the high-potential neurointervention market, which has low penetration and domestic production rates [2]. - Concerns regarding the acquisition include potential short-term dilution of profit margins and pricing issues related to related-party transactions, but regulatory scrutiny reduces the likelihood of unreasonable pricing [2]. - The acquisition is expected to create synergies between neurosurgery and neurointervention channels, significantly expanding the company's growth potential [2]. Group 3: Financial Projections - The company maintains its profit forecasts, expecting net profits of 110 million, 160 million, and 220 million yuan for 2025-2027, representing year-on-year growth rates of 43.8%, 39.0%, and 40.5% respectively [3]. - Corresponding EPS for the same years are projected to be 1.70, 2.36, and 3.32 yuan, with a target price of approximately 90 yuan based on a 38x PE valuation for 2026 [3].